PT-DLBCL presents at an immune-privileged site of the testis with unique characteristics associated with NF-κB pathway signaling, tumor-infiltrating immune cells, and 9p24.1 aberrations, compared with other lymphoma entities.14 This evidence concerns the gene NFKB1 and neoplasm.